Kira: depleting activated dendritic cells

Kira aims to deplete activated dendritic cells for GvHD and autoimmune disease

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression.

Founding CEO Dan Baker told BioCentury Kira Biotech Pty. Ltd. has rights to its lead antibody KB312 and a backup antibody from DendroCyte BioTech Pty. Ltd.

In graft-versus-host-disease (GvHD), activated dendritic cells set off the disease cascade by causing transplanted donor T cells to recognize host cells as

Read the full 784 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE